Supernus, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SUPN | NBIX | AQST | XERS | 2M7C.F | AMPH | |
|---|---|---|---|---|---|---|
| Market cap | 1.64B | 16.81B | 476.94M | 1.91B | 2.87B | 1.19B |
| P/E (TTM) | — | 24.6 | — | — | 14.8 | 16.6 |
| Forward P/E | 6.3 | 13.9 | -6.7 | 53.2 | — | 8.8 |
| Price/book | -55.5 | 4.3 | -6.7 | -186.8 | 1.2 | 1.6 |
| Dividend yield | — | — | — | — | 3.42% | — |
| 1-year change | −11.32% | +7.27% | −38.01% | +35.67% | −24.84% | +15.64% |
| Today | +0.21% | +0.73% | −2.06% | +1.06% | +2.61% | +3.32% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All SUPN news ›Supernus resumed at overweight at Piper Sandler on Indivior merger
Seeking Alpha - Piper Sandler resumed Supernus Pharmaceuticals (SUPN) at overweight, saying that the merger with Indivior announced in August will create "far more business development/M&A firepower than either entity had on its own.
Outgoing Indivior CLO Gets $1.1M In Supernus Merger - Law360 Pulse
Outgoing Indivior CLO Gets $1.1M In Supernus Merger Law360 Try our Advanced Search for more refined results Outgoing Indivior CLO Gets $1.1M In Supernus Merger By Christine DeRosa · November 2, 2026, 4:02 PM EST Want to continue reading?…
Indivior Pharmaceuticals, Inc. completed the acquisition of Supernus Pharmaceuticals, Inc. from group of shareholders in a merger of equals transaction.
Published on 11/02/2026 at 05:53 pm EST BlackRock's Rieder on Global Bonds, AI October 27, 2026 at 04:49 am EDT BlackRock praised for strong results and share buybacks ETFs: The case for a more integrated European ecosystem
Supernus And Indivior Complete Merger Creating A Diversified Cns Biopharmaceutical Leader
TradingView Supernus And Indivior Complete Merger Creating A Diversified Cns Biopharmaceutical Leader
Supernus Announces Third Quarter 2026 Financial Results
ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today…
Supernus Pharmaceuticals GAAP EPS of $0.35 beats by $0.42, revenue of $226.8M beats by $9.24M
Supernus Q3 earnings beat estimates on EPS and revenue, driven by strong growth products. - Supernus Pharmaceuticals press release (SUPN): Q3 GAAP EPS of $0.35 beats by $0.42. - Revenue of $226.8M (+18.1% Y/Y) beats by $9.24M. - Combined…
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 32.4% year on year to $219.1 million. The company’s full-year revenue guidance of…
Supernus Pharmaceuticals Shows Rising Price Performance With Jump To 81 RS Rating
Supernus Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 74 to 81. Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be…
Stocks Generating Improved Relative Strength: Supernus Pharmaceuticals
Supernus Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be unavailable. We…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net5
- seekingalpha.com4
- investors.com3
- law360.com2
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.